Pharmaceutical supply chain compliance has long been viewed as a regulatory burden, but that perception is now shifting significantly across the industry.
The Drug Supply Chain Security Act, known as DSCSA, set a foundational framework for traceability, but trading partners are now discovering its broader operational potential.
Gregg Gorniak has outlined how the industry can move beyond treating DSCSA compliance as a simple regulatory checkbox to unlock genuine shared value.
Serialized data, once collected purely to satisfy regulatory requirements, is now being examined for the operational intelligence it can provide across supply chains.
AI is playing an increasingly prominent role in how pharmaceutical companies analyse and act upon the traceability data generated through DSCSA compliance processes.
RFID technology is also being deployed more widely as trading partners seek faster, more accurate ways to capture and verify serialized product information at scale.
When combined, AI and RFID create a powerful toolkit that allows companies to move from passive data collection toward active, real-time supply chain decision-making.
The shift in thinking represents a maturation of how the pharmaceutical industry approaches traceability infrastructure it was required to build in the first place.
Rather than viewing compliance systems as a sunk cost, forward-looking organisations are treating them as a platform for generating measurable operational improvements.
Trading partners across the supply chain, including manufacturers, wholesalers, and dispensers, stand to benefit when serialized data is shared and leveraged collaboratively.
The ability to track products at the unit level opens up opportunities for reducing waste, improving recall efficiency, and strengthening inventory management practices.
Pharmaceutical companies investing in AI-driven analytics on top of their existing DSCSA infrastructure are positioning themselves for competitive advantage beyond basic compliance.
The broader industry conversation is now focused on how to standardise data sharing practices so that traceability value can be realised consistently across all trading partners.
As the pharmaceutical supply chain continues to evolve, DSCSA compliance is increasingly being reframed not as an endpoint, but as a starting point for deeper operational transformation.